Phase II cemiplimab PD-1 inhibitor trial in incurable NUT carcinoma

This Phase II open-label trial by Northwestern University evaluates cemiplimab—a PD-1 directed monoclonal antibody—in patients with metastatic or unresectable NUT carcinoma lacking standard treatment. Participants receive intravenous cemiplimab every 21 days up to 32 cycles, with imaging and biospecimen collection to monitor safety and clinical activity, exploring a novel immunotherapeutic option for this rare and aggressive tumor.